US › Healthcare

RadNet Inc (RDNT)

US · Healthcare · Diagnostics & Research

$69.22+3.62%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$575.6M

Revenue YoY

+22.1%

Net profit

$-33.5M

Profit YoY

+11.8%

EPS

$-0.28

EPS estimate

$-0.19

Net margin

-5.8%

EPS came in at -0.28 against a street estimate of -0.19 — a miss of 47.4%.

Key statistics

Market cap

$5.25B

Forward P/E

36.6

P/B

4.64

Book value

$14.08

EPS (TTM)

$-0.17

52-week high

$85.84

52-week low

$50.76

50-day MA

$59.26

200-day MA

$66.55

Beta

1.38

Analyst view

Analysts rate RadNet Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $89.75.

Shareholding

Insiders

9.96%

Institutions

100.77%

Largest institutional holders

Fund	Stake
BlackRock Inc	12.82%
RTW INVESTMENTS, LLC	5.47%
T. Rowe Price Associates, Inc.	5.31%
Vanguard Portfolio Management, LLC	4.98%
Beck, Mack & Oliver LLC	4.05%
Vanguard Capital Management, LLC	3.97%
State Street Corp	3.39%
Van Berkom and Associates Inc	2.63%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for RadNet Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.